Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy

Abstract

Background:

Hypertension is an important healthcare challenge, yet despite initiatives to improve detection and advances in therapy, the majority of patients do not achieve recommended blood pressure targets and remain at high cardiovascular risk. Physicians are confronted with an array of antihypertensive agents, accompanied by increasingly complex and often conflicting evidence regarding their efficacy and tolerability.

Scope:

An extensive PubMed and Cochrane database search was conducted to identify clinical literature (published 1990–2009) on the blood pressure lowering efficacy, tolerability and target organ protection of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). While not a systematic review, this article reviews the best available evidence in an attempt to clarify current uncertainty within medical practice regarding treatment options in patients with hypertension.

Findings:

ACEIs have been at the forefront of hypertension therapy for several years, especially in hypertensive at-risk patients. However, their use is restricted by burdensome side-effects and their limited ability to reach target blood pressure. Newer ARBs, such as telmisartan, have more sustained blood pressure control throughout the 24-h dosing period compared with ACEIs and other ARBs. For uncomplicated hypertension, ARBs are preferred to ACEIs because of their superior tolerability and adherence. In specific patient populations, namely heart failure patients, ARBs have previously shown equal cardiovascular protection to ACEIs. ONTARGET showed that an ARB, in this case telmisartan, was as effective as ramipril in reducing cardiovascular events in a wide cross-section of at-risk cardiovascular patients, but was better tolerated even though patients were screened for ACEI tolerance.

Conclusion:

Telmisartan is currently the only ARB to have demonstrated equivalence to ramipril in reducing cardiovascular events in a broad patient population. In practical terms, telmisartan is superior to the reference standard ramipril because of more powerful blood pressure lowering and superior tolerability. However, in many countries, guidance to physicians prioritizes ACEIs. In these countries, telmisartan should be the first choice ARB for hypertensive at-risk patients who do not achieve adequate blood pressure control with an ACEI, or for whom tolerability is a concern.

Key words::

• ACE inhibitor
• Angiotensin receptor blocker
• Antihypertensive
• Blood pressure
• Hypertension

Transparency

Declaration of funding

This review article was funded by Boehringer Ingelheim.

Declaration of financial/other relationships

J.N. has declared that he is a member of the Speakers’ Bureau for Novartis, Pfizer, Bristol Myers Squibb-Sanofi Aventis, Boehringer Ingelheim, Forest and Sankyo.

All peer reviewers receive honoraria from CMRO for their review work. The peer reviewers have disclosed that they have no relevant financial relationships.

Acknowledgments

Editorial assistance was provided by Claire Scarborough, PhD, of PAREXEL MMS, which was funded by Boehringer Ingelheim.